# Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma

> **NCT03487133** · PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 32 (actual)

## Conditions studied

- Relapsed and/or Refractory Cutaneous T-cell Lymphoma

## Interventions

- **DRUG:** bortezomib/dexamethasone

## Key facts

- **NCT ID:** NCT03487133
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-19
- **Primary completion:** 2020-09-30
- **Final completion:** 2020-09-30
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03487133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03487133, "Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03487133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*